Researchers have reported two new studies that could sharpen understanding of how genetics shapes health, with one identifying a marker linked to a serious reaction to a widely used seizure medicine and another mapping more than 1,200 genetic variants tied to major personality traits. The findings, published on September 2, 2026, add to a fast-moving body of work focused on how inherited risk can influence both treatment safety and broader health outcomes.
A drug-safety signal for lamotrigine
In the first study, Vanderbilt Health-led researchers said a genetic marker already used to flag risk of a life-threatening reaction to vancomycin also identifies patients at risk of that reaction to lamotrigine. The team reported that the marker is missing from the gene panels clinicians commonly order before prescribing the epilepsy drug, raising the possibility that some patients may not be screened for a relevant safety risk.
Lamotrigine is widely used in neurological and psychiatric care, making any potential warning sign clinically important. The study does not by itself change prescribing practice, but it suggests that existing genetic testing strategies may need to be reviewed if the association is confirmed in further research.
Personality genetics and what it may reveal
A separate international consortium reported that more than 1,200 different genetic variants are associated with the Big Five personality traits. The researchers also said those personality genetics are linked to dozens of life outcomes, pointing to a wide network of relationships between inherited biology and later health and social patterns.
While personality traits are not medical diagnoses, the study adds to evidence that genetics can influence complex human characteristics in ways that may affect wellbeing across the life course. Researchers caution that such findings do not imply simple cause and effect, but they do help build a more detailed map of how variation in the genome connects with human behaviour and health.
Why the new studies matter for clinicians and patients
Together, the two reports highlight a broader shift in medicine toward more precise, data-driven risk assessment. One points to a possible gap in pre-prescription screening for a serious adverse reaction; the other expands understanding of how genetics may relate to personality and downstream outcomes. For clinicians, the immediate relevance lies in the first finding, which could eventually inform safer use of lamotrigine if replicated and adopted into practice.
For patients, the message is more measured: genetics is increasingly helping researchers identify who may benefit from closer monitoring, but most findings require follow-up before they are translated into routine care. Still, studies like these show how rapidly the field is advancing, with implications for both treatment safety and the growing use of genetic information in medicine.
Photo source: AI-generated or edited image
